RIPK1-ligand-2 is a RIPK1 inhibitor. RIPK1-ligand-2 can be used for synthesis of PROTAC RIPK1 Degrader-1.

KB02-amide-PEG2-C2-acid is a synthesized E3 ligase ligand-linker conjugate that can be used in the synthesis of PROTACs, such as KB02-SLF.

AT-1459 is a selective and orally active direct Thrombin inhibitor with a Ki value of 4.9 nM. AT-1459 exhibits excellent antithrombotic activity in both rat models of venous and arterial thrombosis. AT-1459 can be used for research on thrombosis-related diseases.

Thalidomide-S-C6-acid is a synthetic E3 ligase ligand -linker conjugate, consisting of a thalidomide-based cereblon ligand and one linker. It can be used to synthesize PROTAC Cas9 Degrader-1.

N-Descyclopropanecarbaldehyde Olaparib suberic acid is a ligand-linker conjugate that can be used for the synthesis of DDO3602.

Deoxy-thalidomide-alkyne-hexanoic acid is a E3 ligase ligand-linker conjugate that can be used for synthesis of PROTAC degrader SD-91.

CP-664511 is an orally active and potent α4β1 integrin antagonist with anti-inflammatory effects (IC50=0.52 nM). CP-664511 inhibits the interaction between α4β1 and vascular cell adhesion molecule-1 (VCAM-1), significantly reducing eosinophil infiltration into lung tissue. CP-664511 is promising for research of asthma and allergic airway diseases.

CP-331684 is an orally active agonist of β3-Adrenergic receptor. CP-331684 can be studied in research on obesity.

AM-461 is a DP2 receptor (Prostaglandin Receptor) antagonist. AM-461 can be used for the researches of inflammation and immunology, such as asthma.

PSMA ligand 1 (Compound 1c) is a PSMA ligand with an IC50 of 26.74 nM. The [18F]-labeled PSMA ligand 1 can serve as a PSMA PET tracer and is used in research on the diagnosis of prostate cancer.

CB 3705 is a dihydrofolate reductase (DHFR) and thymidylate synthetase (TS) inhibitor. CB 3705 inhibits L1210 cells and mutant L1210 cell line (L1210:C15) with ID50s of 4.77 μM and 408 μM, respectively.

EMD527040 (hydrochloride) is a highly potent and selective αvβ6 antagonist with anti-fibrotic activity. EMD527040 (hydrochloride) is used in the research of liver cancer and liver fibrosis.

DS21412020 is a fluoroquinolone antibacterial agent. DS21412020 inhibits bacterial DNA gyrase (GyrA) and topoisomerase IV, leading to DNA breaks. DS21412020 exhibits significant activity against Gram-positive bacteria such as Staphylococcus aureus (MIC = 0.006 μg/mL), Streptococcus pneumoniae (MIC = 0.05 μg/mL), and Methicillin)-resistant Staphylococcus aureus (MIC = 0.2 μg/mL), and Gram-negative bacteria such as Escherichia coli (MIC = 0.006 μg/mL) and Pseudomonas aeruginosa (MIC = 0.78 μg/mL). DS21412020 significantly reduces bacterial load in mouse pneumonia and MRSA infection models. DS21412020 can be used in the development of next-generation quinolone antibiotics.

APL-5125 (Compound 61f) is a potent, selective and orally active ATP-competitive CK2α inhibitor with an IC50 of 0.348 nM and a Ki of 0.095 nM. APL-5125 binds to CK2α in a bivalent manner, simultaneously interacting with the ATP-binding site and the αD pocket. APL-5125 exhibits antitumor activity and can be used for the research of cancer, such as colon cancer.

PROTAC BRD4 ligand-4 is a BRD4 ligand, which can be used to synthesize PROTAC BRD4 Degrader-37.

GA-0056 is an angiotensin II receptor blocker. GA-0056 can be used in the research of heart disease.

UK-356202 is a urokinase-type plasminogen activator (uPA) with a Ki value of 0.037 μM. UK-356202 can be used in research related to the topical treatment of chronic ulcerous wounds.

FAK ligand-5 (BI-4464) is a FAK inhibitor, with an IC50 of 25 nM. FAK ligand-5 can serve as a ligand for target protein for PROTAC, used in the development and design of degraders for PROTAC FAK. FAK ligand-5 can be used in the synthesis of PROTAC FAK degrader 4. FAK ligand-5 can be used in cancer research.

E3 Ligase Ligand-linker Conjugate 180 is an E3 ubiquitinase ligand-linker conjugate. E3 Ligase Ligand-linker Conjugate 180 can be used to synthesize KI-CDK9d-32.

ABT-255 hydrochloride is an orally active anti-bacterial agent. ABT-255 hydrochloride exhibits potent in vitro potency (MIC = 0.016-0.031 μg/mL) against drug-susceptible and Rifampin- or Ethambutol-resistant Mycobacterium tuberculosis. ABT-255 hydrochloride shows efficacy against S. aureus, S. pneumoniae and E. coli and reduces viable counts of drug-resistant Mycobacterium tuberculosis in CF-1 mice. ABT-255 hydrochloride can be used for the study of pulmonary tuberculosis.

MRS4917 is an orally active, potent selective P2Y14 receptor (hP2Y14R) antagonist (IC50 = 2.88 nM, Ki = 1.67 nM) that shows >18,000 fold selectivity against P2Y6R (IC50 = 54 μM). MRS4917 demonstrates oral efficacy in reversing established mechanoallodynia in the chronic constriction injury (CCI) mouse model, while having no effect on thermoregulation. MRS4917 can be used for neurological diseases research.

AJI-9561 is a benzoxazole derivative produced by Streptomyces sp. AJI-9561 exhibits cytotoxicity and antibacterial activity. AJI-9561 inhibits the proliferation of Jurkat T cells and mouse P388 leukemia cells, with its IC50 being 0.88 and 1.63 μM respectively. AJI-9561 can be used for research on anti-cancer and antibacterial properties.

FR-158999 is a potent orally active fibrinogen inhibitor. FR-158999 exhibits potent anti-platelet activities with a pIC50 of 7.50. FR-158999 can be used for antithrombotic research.

BMS-180431 is an inhibitor of HMG-CoA reductase (IC50: 43 nM).

ZD 2486 is a glycoprotein IIb/IIIa (GP IIb/IIIa) antagonist. ZD 2486 inhibits platelet aggregation by blocking the binding of fibrinogen to the GP IIb/IIIa receptor on platelets. ZD 2486 can be used for the study of conditions related to unwanted platelet aggregation, such as acute coronary syndrome, unstable angina pectoris, acute myocardial infarction, and complications from cardiovascular interventional procedures[1]

HCV-371 is a highly selective, potent, and low cytotoxicity HCV NSSB (EC50 = 4.8-6.1 μM) polymerase allosteric inhibitor. HCV-371 can be used for research on hepatitis C virus infection.

(R,R)-dWIZ-1 TFA is the the (R,R)-enantiomer of dWIZ-1. dWIZ-1 is a potent WIZ molecular glue degrader. dWIZ-1 has the potential for the research of sickle cell disease (SCD).

Perfluoroenanthic acid (Perfluoroheptanoic acid) is a type of perfluoroalkyl substance (PFAS) that can negatively impact the development of seminiferous tubules and m6A RNA methylation in the testes of offspring mice when exposed during pregnancy, consequently disrupting spermatogenesis and leading to reproductive toxicity. Perfluoroenanthic acid alters the morphology of dendritic spines and synaptic formation in primary cortical neuron cultures, enhancing neuronal activity and synaptic transmission, and increasing the expression of excitatory synapse-related proteins Synaptophysin and PSD95.

ONO-2570366 (Compound 11a) is an antagonist of the cysteinyl leukotriene receptors CysLT1R and CysLT2R (IC50 = 14 nM). ONO-2570366 inhibits the binding of LTD4

J-104132 (L-753037) is a potent, orally active, selective and competitive ETA/ETB receptor antagonist with Ki of 0.034 nM for ETA and 0.104 nM for ETB receptors. J-104132 inhibits Endothelin-1 (ET-1)-induced signaling and vascular contractions in vitro. J-104132 alleviates hypertension, vascular remodeling, and diabetic endothelial dysfunction in vivo by dual ETA/ETB blockade. J-104132 can be used for research on diabetic vascular complications[1][3].